{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:53:38Z","timestamp":1781718818852,"version":"3.54.5"},"reference-count":31,"publisher":"Norwegian Medical Association","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"published-print":{"date-parts":[[2016,12,6]]},"DOI":"10.4045\/tidsskr.16.0128","type":"journal-article","created":{"date-parts":[[2016,12,8]],"date-time":"2016-12-08T09:14:30Z","timestamp":1481188470000},"page":"1889-94","source":"Crossref","is-referenced-by-count":4,"title":["Myeloproliferative neoplasms and JAK2 mutations"],"prefix":"10.4045","volume":"136","author":[{"given":"Henry","family":"Almedal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Vorland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aasne K.","family":"Aarsand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida-Sofie","family":"Gr\u00f8nnings\u00e6ter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ystein","family":"Bruserud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5439-8411","authenticated-orcid":false,"given":"H\u00e5kon","family":"Reikvam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"Mehta J, Wang H, Iqbal SU et al. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma 2014; 55: 595\u2009\u2013\u2009600. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23768070&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.3109\/10428194.2013.813500","DOI":"10.3109\/10428194.2013.813500"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Titmarsh GJ, Duncombe AS, McMullin MF et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol 2014; 89: 581\u2009\u2013\u20097. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24971434&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002\/ajh.23690","DOI":"10.1002\/ajh.23690"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Anderson LA, McMullin MF. Epidemiology of MPN: what do we know? Curr Hematol Malig Rep 2014; 9: 340\u2009\u2013\u20099. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25129052&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007\/s11899-014-0228-z","DOI":"10.1007\/s11899-014-0228-z"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Ghanima W, Knutsen H, Delabie J et al. Prim\u00e6r myelofibrose \u2013 patogenese, diagnostikk og behandling. Tidsskr Nor Legeforen 2013; 133: 1946\u2009\u2013\u200950. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24084971&dopt=Abstract","DOI":"10.4045\/tidsskr.12.1106"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Rampal R, Mascarenhas J. Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm. Curr Opin Hematol 2014; 21: 65\u2009\u2013\u200971. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24366192&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1097\/MOH.0000000000000017","DOI":"10.1097\/MOH.0000000000000017"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"James C, Ugo V, Le Cou\u00e9dic JP et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144\u2009\u2013\u20098. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15793561&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038\/nature03546","DOI":"10.1038\/nature03546"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Baxter EJ, Scott LM, Campbell PJ et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054\u2009\u2013\u200961. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15781101&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/S0140-6736(05)74230-6","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Levine RL, Wadleigh M, Cools J et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387\u2009\u2013\u200997. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15837627&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.ccr.2005.03.023","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Kralovics R, Passamonti F, Buser AS et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779\u2009\u2013\u200990. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15858187&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJMoa051113","DOI":"10.1056\/NEJMoa051113"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Reikvam H, Nepstad I, Tamburini J. Predicting effects of kinase inhibitor in therapy for myeloid malignancies \u2013 the challenges in capturing disease heterogeneity. Expert Opin Investig Drugs 2013; 22: 1365\u2009\u2013\u200970. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24099404&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1517\/13543784.2013.841137","DOI":"10.1517\/13543784.2013.841137"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24: 1128\u2009\u2013\u200938. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20428194&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038\/leu.2010.69","DOI":"10.1038\/leu.2010.69"},{"key":"ref=12","unstructured":"WHO. World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues. 4. utg. Lyon: International Agency for Cancer, 2008."},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Spivak JL, Considine M, Williams DM et al. Two clinical phenotypes in polycythemia vera. N Engl J\u00a0Med 2014; 371: 808\u2009\u2013\u200917. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25162887&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJMoa1403141","DOI":"10.1056\/NEJMoa1403141"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Kiladjian JJ. The spectrum of JAK2-positive myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program 2012; 2012: 561\u2009\u2013\u20096.","DOI":"10.1182\/asheducation.V2012.1.561.3807838"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Reikvam H, Tiu RV. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera. Leukemia 2012; 26: 563\u2009\u2013\u200971. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22076463&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038\/leu.2011.314","DOI":"10.1038\/leu.2011.314"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Larsen TS, Christensen JH, Hasselbalch HC et al. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol 2007; 136: 745\u2009\u2013\u200951. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17313377&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111\/j.1365-2141.2007.06497.x","DOI":"10.1111\/j.1365-2141.2007.06497.x"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Jones AV, Kreil S, Zoi K et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162\u2009\u2013\u20098. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15920007&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1182\/blood-2005-03-1320","DOI":"10.1182\/blood-2005-03-1320"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Scott LM, Tong W, Levine RL et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459\u2009\u2013\u200968. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17267906&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJMoa065202","DOI":"10.1056\/NEJMoa065202"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Pikman Y, Lee BH, Mercher T et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3: e270. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16834459&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1371\/journal.pmed.0030270","DOI":"10.1371\/journal.pmed.0030270"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Nangalia J, Massie CE, Baxter EJ et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391\u2009\u2013\u2009405. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24325359&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJMoa1312542","DOI":"10.1056\/NEJMoa1312542"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379\u2009\u2013\u200990. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24325356&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJMoa1311347","DOI":"10.1056\/NEJMoa1311347"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"Lacout C, Pisani DF, Tulliez M et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006; 108: 1652\u2009\u2013\u200960. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16670266&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1182\/blood-2006-02-002030","DOI":"10.1182\/blood-2006-02-002030"},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"Geetha JP, Arathi CA, Shalini M et al. JAK2 Negative Polycythemia Vera. J Lab Physicians 2010; 2: 114\u2009\u2013\u20096. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21346910&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.4103\/0974-2727.72215","DOI":"10.4103\/0974-2727.72215"},{"key":"ref=24","doi-asserted-by":"crossref","unstructured":"Barbui T, Thiele J, Vannucchi AM et al. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. Blood Cancer J 2015; 5: e337. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26832847&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038\/bcj.2015.64","DOI":"10.1038\/bcj.2015.64"},{"key":"ref=25","unstructured":"Berentsen S. Sekund\u00e6re og relative polycytemier: Indikasjon for venesectio? Indremedisineren 2015; 1: 16\u2009\u2013\u20099."},{"key":"ref=26","doi-asserted-by":"crossref","unstructured":"Pietra D, Li S, Brisci A et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008; 111: 1686\u2009\u2013\u20099. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17984312&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1182\/blood-2007-07-101576","DOI":"10.1182\/blood-2007-07-101576"},{"key":"ref=27","doi-asserted-by":"crossref","unstructured":"Rotunno G, Mannarelli C, Guglielmelli P et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2014; 123: 1552\u2009\u2013\u20095. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24371211&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1182\/blood-2013-11-538983","DOI":"10.1182\/blood-2013-11-538983"},{"key":"ref=28","doi-asserted-by":"crossref","unstructured":"Rumi E, Pietra D, Ferretti V et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2014; 123: 1544\u2009\u2013\u200951. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24366362&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1182\/blood-2013-11-539098","DOI":"10.1182\/blood-2013-11-539098"},{"key":"ref=29","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian R et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391\u2009\u2013\u2009405. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=27069254&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1182\/blood-2016-03-643544","DOI":"10.1182\/blood-2016-03-643544"},{"key":"ref=30","unstructured":"Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppf\u00f8lging av maligne blodsykdommer. http:\/\/legeforeningenno\/Fagmed\/Norsk-selskap-for-hematologi\/Handlingsprogrammer\/ (12.9.2016)."},{"key":"ref=31","doi-asserted-by":"crossref","unstructured":"Borowczyk M, Wojtaszewska M, Lewandowski K et al. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms. Thromb Res 2015; 135: 272\u2009\u2013\u200980. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25559461&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.thromres.2014.11.006","DOI":"10.1016\/j.thromres.2014.11.006"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":["Myeloproliferative neoplasiar og JAK2-mutasjonar"],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:21:32Z","timestamp":1781716892000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2016\/12\/originalartikkel\/myeloproliferative-neoplasiar-og-jak2-mutasjonar"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,6]]},"references-count":31,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2016,12,6]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.16.0128","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,6]]}}}